380 related articles for article (PubMed ID: 26814620)
1. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury.
Han ZA; Song DH; Oh HM; Chung ME
Ann Neurol; 2016 Apr; 79(4):569-78. PubMed ID: 26814620
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury.
Li G; Lv CA; Tian L; Jin LJ; Sun P; Zhao W
Medicine (Baltimore); 2017 May; 96(20):e6919. PubMed ID: 28514309
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
Ranoux D; Attal N; Morain F; Bouhassira D
Ann Neurol; 2008 Sep; 64(3):274-83. PubMed ID: 18546285
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Attal N; de Andrade DC; Adam F; Ranoux D; Teixeira MJ; Galhardoni R; Raicher I; Üçeyler N; Sommer C; Bouhassira D
Lancet Neurol; 2016 May; 15(6):555-65. PubMed ID: 26947719
[TBL] [Abstract][Full Text] [Related]
5. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain.
Han ZA; Song DH; Chung ME
Spinal Cord; 2014 Jun; 52 Suppl 1():S5-6. PubMed ID: 24902645
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis.
Lakhan SE; Velasco DN; Tepper D
Pain Med; 2015 Sep; 16(9):1773-80. PubMed ID: 25800040
[TBL] [Abstract][Full Text] [Related]
7. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.
Zhang H; Lian Y; Ma Y; Chen Y; He C; Xie N; Wu C
J Headache Pain; 2014 Sep; 15(1):65. PubMed ID: 25263254
[TBL] [Abstract][Full Text] [Related]
8. Effect of electrical stimulation on botulinum toxin a therapy in patients with chronic myofascial pain syndrome: a 16-week randomized double-blinded study.
Seo HG; Bang MS; Chung SG; Jung SH; Lee SU
Arch Phys Med Rehabil; 2013 Mar; 94(3):412-8. PubMed ID: 23123438
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome.
Gottsch HP; Miller JL; Yang CC; Berger RE
Neurourol Urodyn; 2011 Jan; 30(1):93-6. PubMed ID: 20589903
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial.
Wu CJ; Lian YJ; Zheng YK; Zhang HF; Chen Y; Xie NC; Wang LJ
Cephalalgia; 2012 Apr; 32(6):443-50. PubMed ID: 22492424
[TBL] [Abstract][Full Text] [Related]
12. A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury.
Lakra C; Cohen H
J Spinal Cord Med; 2022 Sep; 45(5):651-655. PubMed ID: 33263489
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study.
Taylor M; Silva S; Cottrell C
Headache; 2008; 48(10):1476-81. PubMed ID: 19076646
[TBL] [Abstract][Full Text] [Related]
14. Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms.
Ahn SH; Park HW; Lee BS; Moon HW; Jang SH; Sakong J; Bae JH
Spine (Phila Pa 1976); 2003 Feb; 28(4):341-6; discussion 346-7. PubMed ID: 12590206
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A in chronic neuropathic pain in refractory leprosy.
Sousa EJS; Sousa GC; Baia VF; Somensi DN; Xavier MB
Arq Neuropsiquiatr; 2019 May; 77(5):346-351. PubMed ID: 31188999
[TBL] [Abstract][Full Text] [Related]
16. Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models.
Ma L; Nagai J; Sekino Y; Goto Y; Nakahira S; Ueda H
J Pharmacol Sci; 2012; 119(3):282-6. PubMed ID: 22785019
[TBL] [Abstract][Full Text] [Related]
17. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial.
Rieu I; Degos B; Castelnovo G; Vial C; Durand E; Pereira B; Simonetta-Moreau M; Sangla S; Fluchère F; Guehl D; Burbaud P; Geny C; Gayraud D; Ory-Magne F; Bouhour F; Llinares E; Derost P; Marques A; Durif F
Parkinsonism Relat Disord; 2018 Jan; 46():9-15. PubMed ID: 29102441
[TBL] [Abstract][Full Text] [Related]
18. Botulinum Toxin Type-A (Botulax
Kim H; Jang B; Kim ST
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34064451
[TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation.
Intiso D; Basciani M; Santamato A; Intiso M; Di Rienzo F
Toxins (Basel); 2015 Jun; 7(7):2454-80. PubMed ID: 26134256
[TBL] [Abstract][Full Text] [Related]
20. The use of botulinum toxin for spasticity after spinal cord injury.
Marciniak C; Rader L; Gagnon C
Am J Phys Med Rehabil; 2008 Apr; 87(4):312-7; quiz 318-20, 329. PubMed ID: 18356622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
